Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 14Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 52Neoplasms, Plasma Cell 5Neoplasms 4Lymphoma 4Waldenstrom Macroglobulinemia 3Recurrence 3Hematologic Neoplasms 3Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Breast Neoplasms 2Bone Neoplasms 2Back Pain 2Venous Thromboembolism 1Stomatitis 1Skin Neoplasms 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia, Pneumococcal 1Pneumococcal Infections 1Peripheral Nervous System Diseases 1Pain 1Osteoporosis 1Osteonecrosis 1Osteolysis 1Myeloproliferative Disorders 1Multiple Sclerosis 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Sirolimus 1Prednisone 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Skin Neoplasms × Plasma cell × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡